Trending in Longevity

Tirzepatide and Semaglutide now in dedicated longevity trials showing all-cause mortality reduction beyond weight loss. Mainstream longevity breakout of 2026.

DunedinPACE and GrimAge3 now primary endpoints in longevity trials. Biological age reversal tracking via DNA methylation is the dominant research metric of 2026.

Low-dose intermittent rapamycin gaining massive clinical momentum with EVERLAST and ovarian aging trials. The most-discussed mTOR longevity drug in 2026.

Precision senolytics targeting specific senescent cell populations via Fisetin and Quercetin derivatives surging in clinical trials and biohacker communities.

Commercial epigenetic assays becoming standard in preventive care. Annual biological age testing now normalized among longevity-focused individuals and clinics.

Injectable and oral Urolithin A trending for mitophagy activation, muscle endurance, and sleep quality. Timeline Nutrition and Mitopure dominate the space.

Empagliflozin and Dapagliflozin gaining longevity credibility via telomere length preservation and oxidative stress reduction data beyond cardiovascular indications.

Injectable NR gaining attention over oral forms for rapid NAD+ elevation. NMN and NR remain top-searched longevity compounds with strong clinical trial pipeline.

Yamanaka factor-based reprogramming advancing in animal models and early human applications. Altos Labs and Turn Bio leading commercial translation efforts.

Broad mainstream adoption of peptides beyond GLP-1s including BPC-157, TB-500, and Epitalon for immune and metabolic health. Biohacker community driving demand.

Specific 130% O2 at 2.5 ATA protocols trending for telomere lengthening and cognitive function. Israeli HBOT research driving renewed clinical and public interest.

Low-dose methylene blue surging for mitochondrial electron transport support and neuroprotection. Moving from fringe to mainstream longevity clinics in 2026.

TAME trial results anticipated imminently, making Metformin the most-watched longevity drug outcome of 2026. FDA landmark designation for aging indication at stake.

Autologous and allogeneic exosome infusions trending for tissue regeneration and immune modulation. Regulatory momentum and clinic proliferation accelerating in 2026.

Fisetin combined with Urolithin A showing synergistic effects on sleep quality and aging biomarkers. Multiple clinical trials now underway validating senolytic efficacy.

ApoB now the dominant cardiovascular longevity biomarker replacing LDL cholesterol in precision medicine circles. Standard in all longevity clinic panels.

Optimized TRT protocols for healthspan in clinically low-T individuals gaining mainstream acceptance. TRAVERSE trial long-term data reinforcing cardiovascular safety.

TPE showing 2.6-year biological age reduction in recent studies. Ambrosia and new clinical programs driving renewed interest in plasma dilution for longevity.

Specific Akkermansia probiotic strains trending for gut barrier integrity and metabolic reset. Pendulum Glucose Control driving commercial accessibility in 2026.

Photobiomodulation devices for mitochondrial activation trending with growing clinical evidence for skin, brain, and muscle applications among longevity practitioners.

VO2max now recognized as strongest single predictor of longevity. Zone 2 and HIIT protocols for VO2max improvement dominate longevity exercise discourse in 2026.

Non-invasive transcutaneous vagus nerve devices trending for inflammation reduction and autonomic recovery. Nurosym and Truvaga leading consumer device market.

Compounds that suppress SASP without killing senescent cells gaining research traction as safer alternatives to senolytics with fewer side effects in aging tissues.

Blood-based p-tau217 emerging as the most accurate Alzheimer's and brain aging biomarker. FDA-approved blood test rollout in 2025-2026 driving massive clinical interest.

Calcium alpha-ketoglutarate (CaAKG) trending for epigenetic age reduction after high-profile trial data. Sold as Rejuvant and gaining longevity clinic adoption.

MK-677 and other secretagogues trending for muscle growth and IGF-1 restoration. Peptide clinics proliferating amid high demand for legal GH-adjacent compounds.

High-fiber intake optimization strategies for gut microbiome diversity trending as a foundational longevity nutrition approach. Social media driving mainstream adoption.

CGM devices like Dexcom and Libre now standard longevity biohacking tools for metabolic flexibility assessment even in non-diabetic populations.

Quercetin in combination with Dasatinib as the most-studied senolytic protocol in human trials. New derivative compounds improving bioavailability and targeting specificity.

Spermidine for autophagy induction gaining consistent research support and consumer market growth. Longevity labs and wheat germ extracts driving supplement category.

Pig-to-human organ transplantation advancing rapidly following successful kidney and heart xenotransplants. Egenesis and Revivicor driving regulatory and clinical momentum.

Klotho as the anti-aging hormone gaining major research interest. Injectable klotho showing cognitive and physical function improvements in preclinical and early human studies.

ProLon fasting mimicking diet cycles showing epigenetic age reversal in clinical trials. Valter Longo's research driving sustained scientific and consumer interest in 2026.

TRIIM and TRIIM-X trials showing thymus regrowth via GH, DHEA, and Metformin combinations. Regenerating immune youth via thymic involution reversal gaining momentum.